Science News
from research organizations

Transcriptional Coactivators Not Useful As Herpes Antiviral Drug Targets

Date:
March 25, 2009
Source:
Van Andel Research Institute
Summary:
Researchers have determined that the herpes simplex virus type 1 (HSV-1) does not require transcriptional coactivators for viral gene expression early in the infection process. The finding is significant in determining that, in contradiction to earlier models, chemical inhibitors of these cellular proteins are not likely to serve as useful antiviral drugs.
Share:
       
FULL STORY

Researchers at Van Andel Research Institute (VARI) have determined that the herpes simplex virus type 1 (HSV-1) does not require transcriptional coactivators for viral gene expression early in the infection process. The finding is significant in determining that, in contradiction to earlier models, chemical inhibitors of these cellular proteins are not likely to serve as useful antiviral drugs.

Researchers sought to determine how herpes simplex virus “turns on” its viral genes during the first stages of infection. Specifically, they tested whether the expression of the viral genes would be similar to how cellular genes are turned on, and specifically whether the viral genes would depend on a set of cellular proteins called “coactivators.”

“Based on an earlier model we expected that expression of the viral genes would depend on a set of transcriptional coactivators,” said Scientific Investigator Steve Triezenberg, Ph.D., head of the VARI Laboratory of Transcriptional Regulation and co-author of the study published in a recent issue of the Journal of Virology. “As it turns out, we got an unexpected answer.  Using several different approaches, we consistently saw that the coactivator proteins are not required for viral gene expression.”

Researchers have understood that virion protein 16 (VP16) of herpes simplex virus type 1 is a potent transcriptional activator of viral immediate early (IE) genes. However, the role of transcriptional coactivators had not been fully understood.

“This is a significant finding because it tells us that chemical inhibitors of these coactivators are not likely to be good antiviral drugs, despite our earlier model,” said Triezenberg.


Story Source:

The above post is reprinted from materials provided by Van Andel Research Institute. Note: Materials may be edited for content and length.


Cite This Page:

Van Andel Research Institute. "Transcriptional Coactivators Not Useful As Herpes Antiviral Drug Targets." ScienceDaily. ScienceDaily, 25 March 2009. <www.sciencedaily.com/releases/2009/03/090325180707.htm>.
Van Andel Research Institute. (2009, March 25). Transcriptional Coactivators Not Useful As Herpes Antiviral Drug Targets. ScienceDaily. Retrieved August 31, 2015 from www.sciencedaily.com/releases/2009/03/090325180707.htm
Van Andel Research Institute. "Transcriptional Coactivators Not Useful As Herpes Antiviral Drug Targets." ScienceDaily. www.sciencedaily.com/releases/2009/03/090325180707.htm (accessed August 31, 2015).

Share This Page: